

## Touro Scholar

---

NYMC Faculty Publications

Faculty

---

1-1-2018

### From the Cover: 7,8-Dihydroxyflavone Rescues Lead-Induced Impairment of Vesicular Release: A Novel Therapeutic Approach for Lead Intoxicated Children

Xiao-Lei Zhang  
*New York Medical College*

Jennifer L. McGlothan

Omid Miry

Kirstie H. Stansfield

Meredith K. Loth

*See next page for additional authors*

Follow this and additional works at: [https://touro scholar.touro.edu/nymc\\_fac\\_pubs](https://touro scholar.touro.edu/nymc_fac_pubs)

 Part of the [Medicine and Health Sciences Commons](#)

---

#### Recommended Citation

Zhang, X., McGlothan, J., Miry, O., Stansfield, K., Loth, M., Stanton, P., & Guilarte, T. (2018). From the Cover: 7,8-Dihydroxyflavone Rescues Lead-Induced Impairment of Vesicular Release: A Novel Therapeutic Approach for Lead Intoxicated Children. *Toxicological Sciences*, 161 (1), 186-195. <https://doi.org/10.1093/toxsci/kfx210>

This Article is brought to you for free and open access by the Faculty at Touro Scholar. It has been accepted for inclusion in NYMC Faculty Publications by an authorized administrator of Touro Scholar. For more information, please contact [daloia@nymc.edu](mailto:daloia@nymc.edu).

---

**Authors**

Xiao-Lei Zhang, Jennifer L. McGlothan, Omid Miry, Kirstie H. Stansfield, Meredith K. Loth, Patric K. Stanton, and Tomas R. Guilarte

1 7,8-Dihydroxyflavone Rescues Lead-Induced Impairment of Vesicular Release:

2 A Novel Therapeutic Approach for Lead Intoxicated Children

3  
4 Xiao-lei Zhang<sup>1</sup>, Jennifer L. McGlothan<sup>2</sup>, Omid Miry<sup>1</sup>, Kirstie H. Stansfield<sup>3</sup>, Meredith K.  
5 Loth<sup>2,3</sup>, Patric K. Stanton<sup>1</sup>, Tomás R. Guilarte<sup>2\*</sup>

6  
7 <sup>1</sup>Department of Cell Biology & Anatomy

8 New York Medical College

9 Valhalla, NY

10 <sup>2</sup>Department of Environmental & Occupational Health

11 Robert Stempel College of Public Health & Social Work

12 Florida International University

13 Miami, FL

14 <sup>3</sup>Department of Environmental Health Sciences

15 Mailman School of Public Health

16 Columbia University

17 New York, NY

18  
19 \*Correspondence to:

20 Tomás R. Guilarte, Ph.D.

21 Dean, Robert Stempel College of Public Health & Social Work

22 Dept. Environmental & Occupational Health; Cognitive Neuroscience & Imaging

23 Florida International University

24 Miami, FL 33199

25 Phone: 305-348-5344

26 E-mail: [tguilart@fiu.edu](mailto:tguilart@fiu.edu)

27 **ABSTRACT**

28 Lead ( $Pb^{2+}$ ) exposure during brain development inhibits neurotransmitter release  
29 resulting in impaired synapse formation, synaptic plasticity and learning. In primary  
30 hippocampal neurons in culture and hippocampal slices,  $Pb^{2+}$  exposure inhibits vesicular  
31 release and reduces the number of fast-releasing sites, an effect associated with  $Pb^{2+}$   
32 inhibition of NMDA receptor-mediated trans-synaptic BDNF signaling. We hypothesized  
33 that TrkB receptor activation, the cognate receptor for BDNF, would rescue  $Pb^{2+}$ -induced  
34 impairments of vesicular release. Rats were chronically exposed to  $Pb^{2+}$  prenatally and  
35 postnatally until 50 days of age. This  $Pb^{2+}$  exposure paradigm enhanced paired-pulse  
36 facilitation representative of reduced vesicular release probability. Reductions in  $Pb^{2+}$ -  
37 induced release probability were also measured by both mean-variance analysis and  
38 direct two-photon imaging of vesicular release from hippocampal slices. We also found a  
39  $Pb^{2+}$  impairment of calcium influx in presynaptic terminals. Intraperitoneal injections of  
40 the TrkB agonist 7,8-dihydroxyflavone (5 mg/kg) for 14-15 days in  $Pb^{2+}$  rats starting at  
41 postnatal day 35, reversed all  $Pb^{2+}$ -induced impairments of presynaptic transmitter  
42 release at Schaffer collateral-CA1 synapses. These data indicate that *in vivo*  
43 pharmacological activation of TrkB receptors can reverse long-term effects of chronic  
44  $Pb^{2+}$  exposure on presynaptic terminals, pointing to TrkB receptor activation by small  
45 molecules as a promising therapeutic intervention in  $Pb^{2+}$ -intoxicated children.

46  
47 **KEYWORDS**

48 7,8-dihydroxyflavone; vesicular release; lead neurotoxicity

49

50

51

52 Childhood lead ( $\text{Pb}^{2+}$ ) intoxication is a significant public health problem in the United  
53 States and globally<sup>1,2</sup>. Recent episodes of  $\text{Pb}^{2+}$  exposure in children in communities like  
54 Flint, Michigan demonstrate the pervasive nature of the problem<sup>3</sup>. The National  
55 Resources Defense Council (NRDC) reports that millions of Americans get drinking  
56 water from water systems that have  $\text{Pb}^{2+}$  violations and the problem could be much  
57 larger, because systems known to have violations do not show up in government  
58 databases that track such problems. Despite nearly a century of knowledge on the  
59 detrimental effects of  $\text{Pb}^{2+}$  in children's development, the widespread presence of this  
60 poison in the global environment continues to affect children in the most vulnerable and  
61 economically disadvantaged segments of the population.

62

63 Studies have consistently demonstrated that one of the most prominent effects of  $\text{Pb}^{2+}$  in  
64 children is decreased capacity to learn, with devastating effects on cognitive and  
65 intellectual development<sup>4-8</sup>, and in-school performance<sup>9,10</sup>. Early life  $\text{Pb}^{2+}$  intoxication  
66 diminishes intellectual capacity of children with an immeasurable cost to society. Human  
67 studies have shown that  $\text{Pb}^{2+}$  exposure in early life is associated with longitudinal  
68 declines in cognitive function<sup>11</sup>, loss of brain volume<sup>12,13</sup>, and emergence of mental  
69 disorders such as major depression and schizophrenia<sup>14,15</sup>.

70

71 Our laboratory has provided the first working model by which  $\text{Pb}^{2+}$  exposure during the  
72 period of synaptogenesis can affect synapse development and function, that accounts  
73 for both presynaptic and postsynaptic effects of  $\text{Pb}^{2+}$  on the synapse<sup>16-18</sup>. Using a  $\text{Pb}^{2+}$   
74 exposure paradigm during the period of synaptogenesis in primary hippocampal  
75 neurons, we found that  $\text{Pb}^{2+}$  inhibition of postsynaptic NMDA receptors (NMDAR)  
76 impairs CREB-dependent transcription of activity-regulated genes such as brain-derived  
77 neurotrophic factor (BDNF), and alters the function of its cognate receptor TrkB and

78 downstream signaling and alters vesicle movement<sup>16-18</sup>. These studies also showed that  
79  $Pb^{2+}$ -induced impairment of BDNF trans-synaptic retrograde signaling decreases the  
80 presynaptic vesicular proteins synaptophysin and synaptobrevin and inhibits vesicular  
81 release<sup>16</sup>. The addition of exogenous BDNF to  $Pb^{2+}$ -exposed hippocampal neurons  
82 normalized synaptophysin and synaptobrevin levels and reversed the impairment in  
83 vesicular release, providing the first evidence of the beneficial effects of BDNF on  $Pb^{2+}$ -  
84 induced synaptic dysfunction<sup>16</sup>. Consistent with these observations, electrophysiological  
85 and two-photon imaging studies at Schaffer collateral-CA1 synapses in *ex vivo*  
86 hippocampal slices from rats chronically exposed to  $Pb^{2+}$  during development, revealed  
87 a marked inhibition of hippocampal Schaffer-collateral-CA1 synaptic transmission by  
88 inhibiting vesicular release<sup>19</sup>.

89

90 In the present study, we determined whether BDNF activation of its cognate receptor,  
91 TrkB, could rescue the  $Pb^{2+}$ -induced deficits in vesicular release observed in  $Pb^{2+}$   
92 exposed animals *in vivo*. We used 7,8-dihydroxyflavone (7,8-DHF), a small, CNS  
93 permeant molecule from the flavonoid family that is a BDNF mimetic and activates TrkB  
94 receptors<sup>20</sup>. 7,8-DHF exhibits promising therapeutic efficacy in animal models of  
95 neurodegenerative diseases<sup>20-22</sup>. Based on our previous *in vitro* studies demonstrating a  
96 beneficial effect of BDNF on  $Pb^{2+}$ -induced inhibition of vesicular release, we  
97 hypothesized that 7,8-DHF could be useful to assess in our *in vivo*  $Pb^{2+}$  exposure  
98 paradigm. Here we demonstrate that 7,8-DHF can rescue the inhibition of hippocampal  
99 Schaffer-collateral-CA1 vesicular release resulting from developmental  $Pb^{2+}$  exposure.

100

101

102

103

104 **RESULTS**

105 ***Blood Pb<sup>2+</sup> levels and body weight of rats:***

106 The Pb<sup>2+</sup> exposure paradigm did not produce any overt toxicity based on body weight  
107 gain. Body weights at postnatal day 50 (PN50) rats were: 264.4 ± 11.9 g (n=10) for  
108 control animals plus or minus 7,8-DHF and 231.9 ± 10.0 g (n=14) for Pb<sup>2+</sup>-exposed  
109 animals plus or minus 7,8-DHF (p>0.05). Further, blood Pb<sup>2+</sup> levels of littermates to  
110 animals used in this study at PN50 were: 0.6 ± 0.1 µg/dL (n=67) for control animals and  
111 22.2 ± 0.9 µg/dL (n=47) for Pb<sup>2+</sup>-exposed animals. This exposure level is  
112 environmentally relevant and previous studies using this animal model have shown  
113 deficits in synaptic plasticity<sup>23</sup>, decreased adult neurogenesis<sup>24</sup>, and impairments of  
114 spatial learning and contextual fear conditioning<sup>23,25,26</sup>.

115

116 ***7,8-DHF reverses the increase in paired-pulse facilitation at Schaffer collateral-***

117 ***CA1 synapses produced by Pb<sup>2+</sup> exposure:*** Neuronal short-term presynaptic plasticity  
118 is often assessed by delivering paired-pulse stimulation, that is, two stimuli to the same  
119 synaptic pathway in close succession<sup>27,28</sup>. One form of paired-pulse modulation, paired-  
120 pulse facilitation (PPF), is typically attributed to an increase of release probability (*Pr*)  
121 during the second stimulus, arising from prior accumulation of residual Ca<sup>2+</sup> near active  
122 zones and/or lingering effects of Ca<sup>2+</sup> on a Ca<sup>2+</sup> sensor<sup>28,29</sup>. This residual Ca<sup>2+</sup>, when  
123 present at terminals that *fail* to release on the first stimulus, will cause them to release  
124 and increase response amplitude from the second stimulus. Therefore, if initial *Pr* is  
125 reduced, as by manipulations such as reducing extracellular [Ca<sup>2+</sup>], the magnitude of  
126 PPF (the ratio of second to first response amplitude) should increase<sup>28,29</sup>.

127

128 In Figure 1A the black trace shows that PPF in CA1 pyramidal neurons was elicited by  
129 two Schaffer collateral stimuli applied 30 ms apart. The red trace (Figure 1A) shows the  
130 larger PPF typical of a CA1 pyramidal neuron in a slice from a  $Pb^{2+}$  rat ( $Pb^{2+}/VEH$ ) while  
131 the blue trace illustrates rescue of PPF in a slice from a  $Pb^{2+}$  rat that also received 7,8-  
132 DHF ( $Pb^{2+}/7,8-DHF$ ). Administration of 7,8-DHF to control animals (CON/7,8-DHF; grey  
133 trace) did not alter PPF. When paired-pulse stimuli were applied at intervals varying from  
134 20-70 msec, PPF was significantly increased compared to slices from untreated control  
135 rats (One-way ANOVA ( $F(2,29)=9.786$ ,  $p=0.0006$ ). PPF at a paired-pulse interval of 30  
136 ms was significantly increased in slices from  $Pb^{2+}$ -treated rats compared to slices from  
137 control rats (post-hoc Tukey's multiple comparison with Duncan's correction:  $p=0.008$ ).  
138 Moreover, 7,8-DHF treatment of lead exposed rats significantly reduced PPF at this 30  
139 ms interval, compared to rats exposed to lead alone (post-hoc Tukey's multiple  
140 comparison with Duncan's correction:  $p=0.029$ ), or to control rats (post-hoc Tukey's  
141 multiple comparison with Duncan's correction:  $p=0.963$ ), as showed in Figure 1C. One-  
142 way ANOVA with repeated measures demonstrated a statistically significant increase in  
143 PPF at all inter-pulse intervals (Figure 1B red circles;  $p=0.0064$ ) in lead treated rats  
144 compared to controls, while 7,8-DHF administration completely rescued PPF across the  
145 entire paired-pulse profile (Figure 1B, blue circles).

146

147 ***7,8-DHF reverses the impairment in vesicular release from the rapidly-recycling***  
148 ***vesicle pool produced by  $Pb^{2+}$  exposure:*** To directly determine whether presynaptic  
149 vesicular release is altered by *in vivo*  $Pb^{2+}$  exposure, we used two-photon excitation to  
150 visualize release of the styryl dye FM1-43 from the rapidly-recycling pool (RRP) of  
151 presynaptic vesicles after selective loading by hypertonic shock in Schaffer collateral-  
152 CA1 terminals in hippocampal slices. Presynaptic vesicles in the RRP were first  
153 stimulated by a brief hypertonic shock to fuse with the membrane and release their



154 transmitter, which induces them to take up FM1-43 from the extracellular space, followed  
155 by endocytosis and recycling back into the rapidly-recycling pool for the next evoked  
156 release. We have used this method previously to show that generation of long-term  
157 potentiation (LTP) and long-term depression (LTD) is associated with persistent  
158 increases<sup>30</sup> or decreases<sup>31</sup> in the rate of stimulus-evoked FM1-43 de-staining at Schaffer  
159 collateral terminals, and that chronic early life Pb<sup>2+</sup> exposure persistently reduces  
160 vesicular release from the RRP<sup>19</sup>.

161

162 Figure 2 illustrates the effect of Pb<sup>2+</sup> exposure on vesicular release from Schaffer  
163 collateral presynaptic terminals. Figure 2A shows representative pseudocolor images of  
164 FM1-43 labelled Schaffer collateral terminals before (Baseline) and after 12 minutes of 2  
165 Hz stimulation in control slices from rats that received daily injections of vehicle  
166 (CON/VEH) or 7,8-DHF (CON/7,8-DHF), versus slices from Pb<sup>2+</sup> rats with vehicle  
167 (Pb<sup>2+</sup>/VEH) or Pb<sup>2+</sup> rats that received 7,8-DHF (Pb<sup>2+</sup>/7,8-DHF). The slice from the Pb<sup>2+</sup>-  
168 exposed rat showed markedly slower stimulus-evoked de-staining compared to the  
169 control slice, while rapid de-staining was restored in the slice from the Pb<sup>2+</sup> rat that  
170 received 7,8-DHF. Figure 2B summarizes the time courses of all slices, showing the  
171 markedly slower vesicular release evoked by 2 Hz stimulation of Schaffer collateral  
172 terminals in field CA1 of slices from Pb<sup>2+</sup> rats (red filled circles) compared to controls  
173 treated with vehicle (black open circles) or controls treated with 7,8-DHF (grey solid  
174 circles), and the rescue of this effect in slices from Pb<sup>2+</sup> rats treated with 7,8-DHF (blue  
175 solid circles). Statistics with one way ANOVA (F(3,102)=50.73, p<0.0001) on the initial  
176 time constant of release calculated from a single exponential fit of the first 6 times  
177 points<sup>30,31</sup> exhibited a significant slower decay constant in rats exposed to Pb<sup>2+</sup> alone  
178 (red bar, p=0.0001), compared to control rats treated with vehicle (open bar), 7,8-DHF  
179 alone (grey bar, p=0.504), or Pb<sup>2+</sup>-exposed rats also given 7,8-DHF (blue bar, p=0.711).

180

181 **7,8-DHF reverses  $Pb^{2+}$ -induced reductions in presynaptic Schaffer collateral**  
182 **release probability measured by variance-mean analysis:** Variance-mean (VM)  
183 analysis using a binomial model of synaptic transmission has been employed to study  
184 neurotransmitter release probability at a variety of synapses<sup>32,33</sup>. It is typically applied to  
185 steady-state sequences of single evoked EPSCs recorded while varying extracellular  
186  $[Ca^{2+}]$ , or delivering long repetitive trains of stimulation of different frequencies, each  
187 resulting in a range of mean response size with variance that is a parabolic function of  
188  $Pr^{34-37}$ . In this method, low extracellular  $[Ca^{2+}]$  yields low  $Pr$ , release failures and low  
189 EPSC variance, high extracellular  $[Ca^{2+}]$  yields high  $Pr$ , few failures and, again, low  
190 EPSC variance, and physiological extracellular  $[Ca^{2+}]$  yields intermediate  $Pr$  and higher  
191 EPSC variance. We have applied this method to directly estimate presynaptic  $Pr$  at  
192 Schaffer collateral-CA1 synapses, comparing normal slices to slices from  $Pb^{2+}$ -exposed  
193 rats using the identical protocol as in the current study<sup>19</sup>.

194

195 Figure 3A demonstrates that the VM relationship obtained by varying extracellular  $[Ca^{2+}]$   
196 was parabolic, with maximum variance at the peak of the parabola. In pyramidal  
197 hippocampal neurons from  $Pb^{2+}$  rats ( $Pb^{2+}/VEH$ ), individual slice data point (Figure 3A,  
198 red circles) and mean amplitudes (Figure 3B, red circles) at different  $[Ca^{2+}]$ , converted to  
199  $Pr$ , were reduced along the same parabolic fit at all three  $[Ca^{2+}]$ , consistent with a  
200 reduction in presynaptic release probability compared to CON/VEH/7,8-DHF (black open  
201 circles). It should be noted that the CON/VEH/7,8-DHF is the combined data from  
202 CON/VEH and CON/7,8-DHF animals since there was no significant differences  
203 between these two groups. The groups were combined in order to make panel A and B  
204 graphs easier to understand. The actual data for each group is provided in Table 1.

205

206 Across all experiments (Table 1),  $Pr$  calculated by this method was significantly reduced  
207 in slices from  $Pb^{2+}$ /VEH rats at low (1/4 mM,  $p=0.007$ ), medium (2/2 mM,  $p=0.005$ ) and  
208 high (4/1 mM,  $p=0.005$ )  $[Ca^{2+}]/[Mg^{2+}]$  ratios (One-way ANOVA with repeated measures  
209 ( $F(8,69)=25.14$ ,  $p=0.001$ ). Figure 4 shows a variance/mean versus mean linear plot,  
210 where the line fit from pyramidal neurons from a CON/VEH (black dotted line) versus a  
211  $Pb^{2+}$ /VEH (red dotted line) rat significantly differed in slope ( $p=0.015$ ), consistent with a  
212 presynaptic site of reduced  $Pr$ . This shift in slope was rescued in a slice from a  $Pb^{2+}$  rat  
213 treated with 7,8-DHF (Figure 4, blue dotted line). Again, the CON/7,8-DHF data was not  
214 different from CON/VEH and it was not included to simplify the graph, but it is provided  
215 in Table 2. These shifts in  $Pr$  were not associated with significant changes in number of  
216 release sites (N) or quantal size (Q) across all slices (Table 2).

217

218 ***7,8-DHF reverses  $Pb^{2+}$ -induced reductions in presynaptic calcium influx into***  
219 ***Schaffer collateral terminals:*** Calcium channels (P/Q and N-type) are the major source  
220 of action potential mediated  $Ca^{2+}$  influx into presynaptic terminals. Previous studies have  
221 shown that  $Pb^{2+}$  inhibits calcium channels in cultured cells, an effect that is reversible by  
222 washing the cellular preparation<sup>38</sup>. If  $Pb^{2+}$  exposure chronically alters the activity of these  
223 channels, this could indirectly contribute to alterations in  $Pr$ . To directly test whether  
224 chronic  $Pb^{2+}$  exposure produces a persistent inhibition of presynaptic  $Ca^{2+}$  influx, and to  
225 determine if 7,8-DHF can reverse such effects, we injected  $Mg^{2+}$  Green-AM, a calcium  
226 indicator dye that is membrane-permeable<sup>39</sup>, directly into stratum radiatum of field CA1  
227 of hippocampal slices.  $Mg^{2+}$  Green positive fluorescent puncta were visualized in field  
228 CA1 using two-photon excitation. Figure 5 demonstrates the kinetics of  $Mg^{2+}$  Green  
229 fluorescence increases in response to a 100 Hz burst of four Schaffer collateral stimuli.  
230 We have shown previously that these responses persist in the presence of NMDA and  
231 AMPA receptor antagonists, despite the loss of fEPSPs, are blocked by cadmium and

232 omega conotoxin, and co-localize with FM4-64, confirming a presynaptic nature for  
233 these calcium transients<sup>40</sup>.

234

235 Comparison of mean fluorescence increases of representative stimulus-evoked  
236 presynaptic Ca<sup>2+</sup> influx transients in Schaffer collateral terminals in slices from vehicle  
237 control (CON/VEH; Figure 5A black trace) or control treated with 7,8-DHF (CON/7,8-  
238 DHF; Figure 5A grey trace), versus Pb<sup>2+</sup> rats (Pb<sup>2+</sup>/VEH; Figure 5A red trace) and Pb<sup>2+</sup>  
239 rats treated with 7,8-DHF (Pb<sup>2+</sup>/7,8-DHF; Figure 5A, blue trace), revealed that action  
240 potential-dependent Ca<sup>2+</sup> influx was reduced in amplitude by Pb<sup>2+</sup> exposure, and that  
241 7,8-DHF was able to reverse this reduction in presynaptic Ca<sup>2+</sup> influx. Figure 5B  
242 summarizes these results across all slices, showing that Schaffer collateral presynaptic  
243 terminals in hippocampal slices from Pb<sup>2+</sup> rats (red bar) exhibited reduced Ca<sup>2+</sup> influx  
244 (One-way ANOVA with repeated measures F(3,28)=5.233, p=0.0054) compared to  
245 vehicle control slices (black bar, p=0.0129), 7,8-DHF treated slices (grey bar, p=0.0192),  
246 or slices from rats exposed to Pb<sup>2+</sup> plus 7,8-DHF injections (blue bar, p=0.0269). Taken  
247 together, our data indicate that chronic exposure to Pb<sup>2+</sup> during development results in a  
248 persistent reduction in presynaptic *Pr* that may be due to both reduced Ca<sup>2+</sup> influx, and  
249 actions downstream of presynaptic Ca<sup>2+</sup> influx at the level of SNARE protein-mediated  
250 exocytosis<sup>16-18</sup>. Consistent with its effects in rescuing *Pr*, daily injection of 7,8-DHF was  
251 also able to rescue the effects of Pb<sup>2+</sup> exposure in reducing presynaptic Ca<sup>2+</sup> influx at  
252 Schaffer collateral terminals in the hippocampus.

253

254

255

256

257

258 **DISCUSSION**

259 Our current study identifies a novel therapeutic target with the potential to treat Pb<sup>2+</sup>-  
260 intoxicated children. Daily postnatal administration of the cell permeant TrkB receptor  
261 agonist 7,8-DHF, which readily crosses the blood-brain barrier, completely rescued Pb<sup>2+</sup>-  
262 induced reductions in vesicular release and presynaptic Ca<sup>2+</sup> influx, supporting its  
263 potential as a novel treatment for the cognitive effects of early life Pb<sup>2+</sup> exposure. 7,8-  
264 DHF is a naturally occurring small molecule in the flavonoid family of polyphenolic  
265 compounds found in *Godmania aesculifolia*, *Tridax procumbens*, and primula tree  
266 leaves<sup>41,42</sup>. It has been shown to be neuroprotective in preclinical studies<sup>43,44</sup>. However,  
267 further studies are needed to determine whether the rescue of transmitter release by  
268 7,8-DHF is long-lasting or permanent, and whether it rescues behavioral impairments  
269 associated with chronic developmental exposure to Pb<sup>2+</sup>.

270

271 Previous studies using acute exposure to Pb<sup>2+</sup> in cultured cells have shown inhibition of  
272 Ca<sup>2+</sup> channels by Pb<sup>2+</sup>, an effect that is reversed upon washout of Pb<sup>2+</sup> from the cells<sup>38</sup>.  
273 There could be additional mechanisms by which Pb<sup>2+</sup> persistently alters vesicular  
274 release, such as changes in levels of SNARE proteins that we have shown  
275 previously<sup>16,17</sup>. In this study, fluorescent imaging of presynaptic Ca<sup>2+</sup> influx showed that  
276 Pb<sup>2+</sup> exposure was associated with reductions in voltage-dependent Ca<sup>2+</sup> channel-  
277 mediated Ca<sup>2+</sup> entry that were completely reversed by 7,8-DHF. Previously, we found  
278 that presynaptic Ca<sup>2+</sup> fluorescent signals evoked by brief 20 Hz bursts of stimulation  
279 showed only a small, early reduction in amplitude of presynaptic Ca<sup>2+</sup> signals in slices  
280 from Pb<sup>2+</sup> rats<sup>19</sup>, leading us to use higher frequency 100 Hz bursts of stimulation in this  
281 study. Our present findings suggest that developmental Pb<sup>2+</sup> exposure can persistently  
282 impair presynaptic Ca<sup>2+</sup> entry, and have additional downstream effects at the level of  
283 vesicular SNARE protein-mediated docking, recycling, and long-term stability of the

284 release complex, consistent with our previous findings in hippocampal neuronal  
285 cultures<sup>16</sup>, and hippocampal slices from Pb<sup>2+</sup> rats<sup>19</sup>.

286

287 In this study, rats were exposed to Pb<sup>2+</sup> chronically during gestation, postnatally and  
288 continuing through to young adulthood. The artificial cerebrospinal fluid used to maintain  
289 slice viability during experiments did not contain Pb<sup>2+</sup>, indicating that the effects  
290 observed were the result of the *in vivo* Pb<sup>2+</sup> exposure. Our studies have previously  
291 shown<sup>16</sup> that BDNF synthesis and release are decreased in cultured hippocampal  
292 neurons exposed to Pb<sup>2+</sup>, and are associated with reductions in levels of SNARE  
293 proteins and inhibition of vesicular release. These effects of *in vitro* Pb<sup>2+</sup> exposure, were  
294 rescued by exogenous BDNF, consistent with our present findings. Stansfield et al.<sup>18</sup>,  
295 using the same Pb<sup>2+</sup> exposure paradigm in cultured neurons, showed that Pb<sup>2+</sup> may  
296 impair the transport of BDNF-containing vesicles, possibly by altering Huntingtin  
297 phosphorylation at a site promoting anterograde BDNF vesicle movement. This effect of  
298 Pb<sup>2+</sup> resulted in impaired BDNF release, decreasing TrkB activation, and  
299 phosphorylation of synapsin I. Our current findings further support the hypothesis that  
300 BDNF receptor agonists and treatments such as enriched environments that increase  
301 BDNF levels and release<sup>45,46</sup>, may be able to rescue the effects of chronic Pb<sup>2+</sup> exposure  
302 we observed in more intact hippocampal synaptic networks. Further, previous studies  
303 from our laboratory have shown that environmental enrichment can reverse Pb<sup>2+</sup>-  
304 induced impairments of spatial learning in rats of similar age and Pb<sup>2+</sup> treatment<sup>47</sup>. This  
305 study also showed that Pb<sup>2+</sup>-exposed rats placed in an enriched environment that  
306 reverses learning deficits, also exhibit increased BDNF gene expression in the  
307 hippocampus<sup>47</sup>, supporting our current data implicating the BDNF-TrkB system in Pb<sup>2+</sup>  
308 neurotoxicity and suggesting the BDNF mimetic 7,8-DHF as a potential therapy for Pb<sup>2+</sup>-  
309 intoxicated children.

310

311 **METHODS**

312 Chemicals: Chemicals for extra- and intracellular solutions were purchased from Sigma-  
313 Aldrich (St. Louis, MO). Neurotransmitter receptor antagonists were purchased from  
314 Tocris Cookson (Minneapolis, MN), and FM1-43 from Invitrogen (Grand Island, NY).

315

316 Blood Pb<sup>2+</sup> analysis: Blood Pb<sup>2+</sup> levels in samples from littermates were measured using  
317 the LeadCare system (Magellan Diagnostics, N. Billerica, MA).

318

319 Animals: Adult female Long-Evans rats (250 g) were purchased from Charles River, Inc.  
320 (Wilmington, MA) and randomly placed on diet containing 0 (control) or 1500 ppm lead  
321 acetate (PbAc) (Dyets, Bethlehem, PA) 10 days prior to breeding with non-exposed  
322 Long-Evans males (300 g). Litters were culled to 10 pups on postnatal day 1 (PN1).  
323 Dams were maintained on their respective diet and at PN21 male pups were weaned  
324 onto the same diet and maintained until PN50. All rats are housed in plastic cages at 22  
325 ± 2°C on a 12/12 light:dark cycle. Food and water were allowed ad libitum. Each litter is  
326 a single experimental unit for statistical purposes, so that for each experiment only one  
327 animal per litter was used for one data point. All studies were conducted in accordance  
328 with the United States Public Health Service's Policy on Human Care and Use of  
329 Laboratory Animals under protocols approved by Institutional Animal Care and Use  
330 Committees from each university.

331

332 Hippocampal slice electrophysiology: Experiments were conducted as described  
333 previously<sup>19,30,31</sup>. At 50 ± 2 days of age, rats were deeply anesthetized with isoflurane,  
334 decapitated and their brains rapidly removed and submerged in ice-cold artificial  
335 cerebrospinal fluid (ACSF, 2–4 °C), containing (in mM): 124 NaCl, 4 KCl, 2 MgCl<sub>2</sub>, 2

336 CaCl<sub>2</sub>, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 26 NaHCO<sub>3</sub>, 10 glucose; at pH 7.4, gassed continuously with  
337 95% O<sub>2</sub>/5% CO<sub>2</sub>). Brains were hemisected, the frontal lobes cut off, and individual  
338 hemispheres glued using cyanoacrylate adhesive onto a stage immersed in ice-cold  
339 ACSF gassed continuously with 95% O<sub>2</sub>/5% CO<sub>2</sub> during slicing. We cut 400 μm thick  
340 coronal slices using a vibratome (Leica VT1200S), and transferred them to an interface  
341 holding chamber for incubation at room temperature for a minimum of 1 hr before  
342 transferring to a submerged recording chamber continuously on a Zeiss Axioskop  
343 microscope continuously perfused at 3 ml/min with oxygenated ACSF at 32 ± 0.5 °C.

344

345 Whole cell patch-clamp recordings were performed in CA1 pyramidal neurons using  
346 standard techniques. Patch pipettes (R=3-4 MΩ) were filled with recording solution  
347 containing (in mM): 135 CsMeSO<sub>3</sub>, 8 NaCl, 10 HEPES, 2 Mg-ATP, 0.3 Na-GTP, 0.5  
348 EGTA, and 1 QX-314 (275 mOsm, pH 7.25 adjusted with Cs(OH)<sub>2</sub>). Access resistance  
349 was carefully monitored, and only cells with stable access resistance (<5% change)  
350 were included in analyses. CA1 pyramidal cells were recorded under voltage clamp  
351 using a MultiClamp 700B (Axon Instruments) with Clampex (v9). Recording signals were  
352 filtered through an eight-pole Bessel low-pass filter with a 3 kHz cutoff frequency,  
353 digitized at 10 kHz, and sampled using Clampex (v9). Neurons were clamped at -60  
354 mV, and Schaffer collateral-evoked EPSCs were delivered by a bipolar stimulating  
355 electrode (FHC, USA, 50-100 pA, 100 μs duration). EPSC slopes were calculated by  
356 linear interpolation of the initial downward current from 20% to 80% of the maximum  
357 EPSC amplitude. Paired-pulse facilitation was assessed by applying a pair of Schaffer  
358 collateral stimuli at intervals of 10-125 msec, and the ratio of slopes of the second to the  
359 first response was calculated, so that numbers greater than 1.0 represented facilitation,  
360 less than 1.0 inhibition.

361



362

363

364 Two-photon laser scanning microscopy

365 Vesicular release FM1-43 fluorescence measurements: Fluorescence was visualized  
366 using a customized two-photon laser-scanning Olympus BX61WI microscope with a  
367 60x/0.90W water immersion infrared objective lens and an Olympus multispectral  
368 confocal laser scan unit. The light source was a Mai-Tai™ laser (Solid-State Laser Co.,  
369 Mountain View, CA), tuned to 860 nm for exciting Magnesium Green and 820 nm for  
370 exciting FM1-43. Epifluorescence was detected with photomultiplier tubes of the  
371 confocal laser scan head with pinhole maximally opened and emission spectral window  
372 optimized for signal over background. In the transfluorescent pathway, a 565 nm dichroic  
373 mirror was used to separate green and red fluorescence to eliminate transmitted or  
374 reflected excitation light (Chroma Technology, Rockingham, VT). After confirming the  
375 presence of Schaffer collateral-evoked fEPSPs >1 mV in amplitude in CA1 *stratum*  
376 *radiatum*, and inducing LTP, 10 μM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) was  
377 bath-applied throughout the rest of the experiment to prevent synaptically-driven action  
378 potentials in CA3 pyramidal neurons from accelerating dye release. Presynaptic boutons  
379 were loaded by bath-applying 5 μM FM1-43 (Molecular Probes) in hypertonic ACSF  
380 supplemented with sucrose to 800 mOsm for 25 sec to selectively load the rapidly-  
381 recycling pool (RRP)<sup>30,31</sup>, then returned to normal ACSF. Stimulus-induced destaining  
382 was measured after 30 min perfusion with dye-free ACSF, by bursts of 10 Hz bipolar  
383 stimuli (150 μs DC pulses) for 2 sec applied once each 30 sec. We fitted a single  
384 exponential to the first 6 fluorescence time course values, and decay time constants  
385 between groups compared by two-tailed Student's t-test, as we have shown previously  
386 that the early release reflects vesicular release from the RRP prior to recycling and  
387 reuse of vesicles<sup>30,31</sup>.

388

389 Presynaptic  $Ca^{2+}$  influx fluorescence measurements: Using established methods for  
390 measuring  $[Ca^{2+}]$  transients<sup>48</sup>, we filled Schaffer collateral presynaptic fibres with  
391 Magnesium Green AM. Briefly, an ejection electrode (tip diameter, 5-10  $\mu$ m) containing  
392 Magnesium Green AM (1 mM Magnesium Green AM, 10% DMSO, 1% pluronic acid in  
393 ACSF) was lowered into the Schaffer collateral pathway between the stimulating  
394 electrode and the presynaptic terminal field to be observed, air pressure pulses (6-9 psi,  
395 100-200 msec) controlled by a Picospritzer (General Valve Corp. USA) were applied to  
396 the electrode until a small bright spot ( $\approx$ 10  $\mu$ m in diameter) was observed. Thirty  
397 minutes elapsed to allow dye to sufficiently diffuse into presynaptic boutons prior to  
398 commencing imaging. To verify that magnesium green selectively loaded presynaptic  
399 terminals, FM4-64 was loaded with high  $[K^+]_o$  at the end of the experiment. To measure  
400  $Ca^{2+}$  dynamics, stimulus-evoked fluorescence signals were collected by scanning at 200  
401 Hz in surface-scanning mode (XYT). Baseline fluorescence ( $F_0$ ) was averaged over four  
402 images, and  $\Delta F/F$  calculated as  $(\Delta F/F)_{(t)}=(F_{(t)}-F_0)/F_0$ .

403

404 Estimation of presynaptic release probability by variance-mean (VM) analysis: Variance-  
405 mean (VM) analysis according to a binomial model of synaptic transmission is a method  
406 that has been employed to study transmitter release at many synapses<sup>32,33,49</sup>. It is mainly  
407 applied to steady-state sequences of evoked EPSCs recorded under a variety of  
408 conditions by varying extracellular  $[Ca^{2+}]_o$ , or delivering long repetitive trains of stimulation  
409 of different frequencies, each resulting in a range of mean response size<sup>34-37</sup>.

410

411 We used three ratios of  $[Ca^{2+}]/[Mg^{2+}]$  in ACSF (4/1, 2/2, and 1/4 mM) to alter release  
412 probability at Schaffer collateral synapses. Experiments began by establishing stable  
413 whole-cell recording from a CA1 pyramidal neuron, and then perfusing the slice with 4/1

414  $[Ca^{2+}]/[Mg^{2+}]$  ACSF. Cells were voltage-clamped at -65 mV, and 100  $\mu$ s constant-current  
415 stimulus pulses were delivered to Schaffer collateral/commissural fiber axons every 10  
416 sec to evoke an EPSC. Stable recordings for 8-10 min were made in 4/1  $[Ca^{2+}]/[Mg^{2+}]$ ,  
417 before replacing the perfusate with 1/4 mM  $[Ca^{2+}]/[Mg^{2+}]$  ACSF. After EPSCs decreased  
418 in amplitude and restabilized, which usually took 5-8 min, EPSCs were recorded for an  
419 additional 8 min. Slices were then perfused with 2/2 mM  $[Ca^{2+}]/[Mg^{2+}]$  ACSF. After EPSC  
420 amplitudes had again stabilized, another 8 min of recordings were made. To induce  
421 LTD, slices were exposed to either 10  $\mu$ M NMDA or 25  $\mu$ M DHPG in 2/2 mM  
422  $[Ca^{2+}]/[Mg^{2+}]$  ACSF for three or five min, respectively, durations which reliably induced  
423 LTD lasting hours. After drug exposure, slices were perfused with 2/2 mM  $[Ca^{2+}]/[Mg^{2+}]$   
424 ACSF for >30 min, to verify expression of LTD, and then the same sequence of  
425  $[Ca^{2+}]/[Mg^{2+}]$  ACSF applications was repeated. To ensure that postsynaptic AMPA  
426 receptors were responding to non-saturating glutamate concentration, a requirement for  
427 VM analysis, experiments were performed in a low concentration of the AMPA receptor  
428 antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX, 100 nM).

429

#### 430 7,8-DHF administration:

431 7,8-Dihydroxyflavone hydrate (DHF, Sigma-Aldrich, St Louis, MO) was dissolved in  
432 phosphate-buffered saline (PBS) containing 17% dimethylsulfoxide (DMSO). Male rats  
433 received daily intraperitoneal injections of 5 mg/kg 7,8-DHF or 17% DMSO vehicle daily  
434 for 14-15 consecutive days starting when they were 35-42 days of age. Rats were  
435 sacrificed for slice preparation twenty-four hours after the last 7,8-DHF administration.

436

437 Statistics: Power analysis showed a group size of 6 animals per treatment group with  
438 significance level pre-set to  $p < 0.05$  could detect between group differences of 10% for  
439 vesicular transmitter release time constants and release probability at a power of 85%

440 with typical parameter standard deviations. Data sets did not deviate significantly from  
441 normal distribution (D'Agostino-Pearson omnibus normality test), and did not exhibit  
442 significant differences in parameter variances (F-test). Slices and treatments were  
443 randomized, with treated and control slices examined in parallel on the same or  
444 sequential days. While all analyses were automated, the investigator was not blinded to  
445 treatment group. Student's t-test was used to determine differences between the control  
446 and  $Pb^{2+}$  treated groups for each particular measure. In analyses requiring comparisons  
447 between multiple groups, a one-way ANOVA with Sidak's Multiple Comparisons analysis  
448 was used with post-hoc Tukey's test for individual group comparisons. Significance level  
449 was preset to  $p < 0.05$ .

450

451 Data Availability: Following calculation of EPSP slopes, paired-pulse ratios or optical  
452 time courses of vesicular release and presynaptic calcium influx, all data will be made  
453 available upon request. Image analysis was performed with ImageJ (NIH), statistical  
454 analyses with GraphPad Prism v6 (La Jolla, CA), and custom-built, proprietary software  
455 was used to control the multi-photon laser scanner for FM1-43 imaging experiments,  
456 which is copyrighted by the designer and cannot be made available.

457

458

459

460

461

462

463

464

465

466

467

468

469 **ACKNOWLEDGEMENTS:** This work was supported by grants ES006189 and  
470 ES020465 from the National Institute of Environmental Health Sciences to TRG.

471

472 **AUTHOR CONTRIBUTIONS:**

473 X.Z.: experimental planning, analysis and execution; writing and editing of manuscript.

474 J.L.M.: experimental planning and execution; writing and editing of manuscript. O.M.:

475 experimental execution; K.H.S.: experimental execution; M.K.L.: experimental execution;

476 P.K.S.: experimental planning, analysis, and direction; writing and editing of manuscript;

477 T.R.G.: conceptualized overall studies and received funding, experimental planning and

478 direction of study; writing and editing of manuscript.

479

480 **COMPETING INTERESTS:**

481 The authors declare no competing financial interests.

482

483

484 **REFERENCES**

- 485 1. Tong, S., von Schirnding, Y.E. & Prapamontol, T. Environmental lead exposure: a  
486 public health problem of global dimensions. *Bull. World Hlth. Org.* 78, 1068-1077  
487 (2000).
- 488 2. Toscano, C.D. & Guilarte, T.R. Lead Neurotoxicity: From Exposure to Molecular  
489 Effects. *Brain Res. Rev.* 49, 529-554 (2005).
- 490 3. Hanna-Atisha, M., LaChance, J., Sadler, R.C. & Champney Schnepf, A. Elevated  
491 blood lead levels in children associated with the Flint drinking water crisis: A spatial  
492 analysis of risk and public health response. *Am. J. Public Health* 106, 283-290  
493 (2016).
- 494 4. Bellinger, D.C., Stiles, K.M. & Needleman, H.L. Low level lead exposure, intelligence  
495 and academic achievement: a long term follow up. *Pediatrics* 90, 855-861 (1992).
- 496 5. Canfield, R.L., Henderson, C.R. Jr., Cory-Slechta, D.A., Cox, C., Jusko, T.A. &  
497 Lanphear, B.P. Intellectual impairment in children with blood lead concentrations  
498 below 10 ug per deciliter. *N. Engl. J. Med.* 348, 1517-1526 (2003).
- 499 6. Lanphear, B.P., Hornung, R., Khoury, J., Yolton, K., Baghurst, P., Bellinger, D.C.,  
500 Canfield, R.L., Dietrich, K.N., Bornschein, R., Greene, T., Rothenberg, S.J.,  
501 Needleman, H.L., Schnaas, L., Wasserman, G., Graziano, J. & Roberts, R. Low-level  
502 environmental lead exposure and children's intellectual function: An international  
503 pooled analysis. *Environ. Health Perspect.* 113, 894-899 (2005).
- 504 7. Jusko, T.A., Henderson, C.R., Lanphear, B.P., Cory-Slechta, D.A., Parsons, P.J. &  
505 Canfield, R.L. Blood lead concentrations < 10 ug/dl and child intelligence at 6 years  
506 of age. *Environ. Health Perspect.* 116, 243-248 (2008).
- 507 8. Schwartz, B.S., Stewart, W.F., Bolla, K.I., Simon, P.D., Bandeen-Roche, K., Gordon,  
508 P.B., Links, J.M. & Todd, A.C. Past adult lead exposure is associated with  
509 longitudinal decline in cognitive function. *Neurology* 55, 1144-1150 (2000).

- 510 9. Magzamen, S., Imm, P., Amato, M.S., Havlena, J.A., Anderson, H.A., Moore, C.F. &  
511 Kanarek, M.S. Moderate lead exposure and elementary school end-of-grade  
512 examination performance. *Ann. Epidemiol.* 23, 700-707 (2013).
- 513 10. Evens, A., Hryhorczuk, D., Lanphear, B.P., Rankin, K.M., Lewis, D.A., Forst, L. &  
514 Rosenberg, D. The impact of low-level lead toxicity on school performance among  
515 children in the Chicago Public Schools: a population-based retrospective cohort  
516 study. *Environ. Health* 14, 21 (2015).
- 517 11. Stewart, W.F., Schwartz, B.S., Davatzikos, C., Shen, D., Liu, D., Wu, X., Todd, A.C.,  
518 Shi, W., Bassett, S. & Youssef, D. Past adult lead exposure is linked to  
519 neurodegeneration measured by brain MRI. *Neurology* 66, 1476-1484 (2006).
- 520 12. Cecil, K.M., Brubaker, C.J., Adler, C.M., Dietrich, K.N., Altaye, M., Egelhoff, J.C.,  
521 Wessel, S., Elangovan, I., Hornung, R., Jarvis, K. & Lanphear, B.P. Decreased brain  
522 volume in adults with childhood lead exposure. *PLoS Med.* 5, e112 (2008).
- 523 13. Rizzoli, S.O. & Betz, W.J. Synaptic vesicle pools. *Nat. Rev. Neurosci.* 6, 57-69  
524 (2005).
- 525 14. Bouchard, M.F., Bellinger, D.C, Weuve, J., Matthews-Bellinger, J., Gilman, S.E.,  
526 Wright, R.O., Schwartz, J. & Weisskopf, M.G. Blood lead levels and major  
527 depressive disorder, panic disorder, and generalized anxiety disorder in US young  
528 adults. *Arch. Gen. Psychiatry* 66, 1313-1319 (2009).
- 529 15. Guilarte, T.R., Opler, M. & Pletnikov, M. Is lead exposure in early life an  
530 environmental risk factor for schizophrenia? Neurobiological connections and  
531 testable hypotheses. *Neurotoxicology* 33, 560-574 (2012).
- 532 16. Neal, A.P., Stansfield, K.H., Worley, P.F., Thompson, R.E. & Guilarte, T.R. Lead  
533 exposure during synaptogenesis alters vesicular release proteins and impairs  
534 vesicular release: potential role of NMDA receptor-dependent BDNF signaling.  
535 *Toxicol. Sci.* 116, 249-263 (2010).

- 536 17. Neal, A.P. & Guilarte, T.R. Molecular Neurobiology of Pb<sup>2+</sup>: effects on synaptic  
537 function. *Mol. Neurobiol.* 42, 151-160 (2010).
- 538 18. Stansfield, K.H., Pilsner, J.R., Lu, Q., Wright, R.O. & Guilarte, T.R. Dysregulation of  
539 BDNF-TrkB signaling in developing hippocampal neurons by Pb<sup>2+</sup>: implications for an  
540 environmental basis of neurodevelopmental disorders. *Toxicol. Sci.* 127, 277-295  
541 (2012).
- 542 19. Zhang, X.L., Guariglia, S.R., McGlothan, J.L., Stansfield, K.H., Stanton, P.K. &  
543 Guilarte, T.R. Presynaptic mechanisms of lead neurotoxicity: effects on vesicular  
544 release, vesicle clustering and mitochondrial number. *PLoS ONE* 10, e0127461  
545 (2015).
- 546 20. Liu, C., Chan, C.B. & Ye, K. 7,8-dihydroxyflavone, a small molecular TrkB agonist, is  
547 useful for treating various BDNF-implicated human disorders. *Transl. Neurodegener.*  
548 5, 2 (2016).
- 549 21. Devi, L. & Ohno, M. 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses  
550 memory deficits and BACE1 elevation in a mouse model of Alzheimer's disease.  
551 *Neuropsychopharmacology* 37, 434-444 (2012).
- 552 22. Jiang, M., Peng, Q., Liu, X., Jin, J., Hou, Z., Zhang, J., Mori, S., Ross, C.A., Ye, K. &  
553 Duan, W. Small-molecule TrkB receptor agonists improve motor function and extend  
554 survival in a mouse model of Huntington's disease. *Hum. Mol. Genet.* 22, 2462-2470  
555 (2013).
- 556 23. Nihei, M.K., Desmond, N.L., McGlothan, J.L., Kuhlmann, A.C. & Guilarte, T.R. N-  
557 methyl-D-aspartate receptor subunit changes are associated with lead-induced  
558 deficits of long-term potentiation and spatial learning. *Neuroscience* 99, 233-242  
559 (2000).



- 560 24. Verina, T., Rohde, C.A. & Guilarte, T.R. Environmental lead exposure during early  
561 life alters granule cell neurogenesis and morphology in the hippocampus of young  
562 adult rats. *Neuroscience* 145, 1037-1047 (2007).
- 563 25. Kuhlmann, A.C., McGlothan, J.L. & Guilarte, T.R. Developmental lead exposure  
564 causes spatial learning deficits in adult rats. *Neurosci. Lett.* 233, 101-104 (1997).
- 565 26. McGlothan, J.L., Karcz-Kubicha, M. & Guilarte, T.R. Developmental lead exposure  
566 impairs extinction of conditioned fear in young adult rats. *NeuroToxicology* 29, 1127-  
567 1130 (2008).
- 568 27. Andersen, P. & Lømo, T. Control of hippocampal output by afferent volley frequency.  
569 *Progress in Brain Research: Structure and Function of the Limbic System*, eds  
570 Tokizane, T. & Adey, R.W. (Elsevier Science), 400-412 (1967).
- 571 28. Zucker, R.S. Short-term plasticity. *Annu. Rev. Neurosci.* 12, 13-31 (1989).
- 572 29. Neher, E. Vesicle pools and Ca<sup>2+</sup> microdomains: new tools for understanding their  
573 roles in neurotransmitter release. *Neuron* 20, 389-399 (1998).
- 574 30. Stanton, P.K., Winterer, J. & Müller, W. Imaging LTP of presynaptic release of FM1-  
575 43 from the rapidly-recycling vesicle pool at Schaffer collateral-CA1 synapses in rat  
576 hippocampal slices. *Eur. J. Neurosci.* 22, 2451-2461 (2005).
- 577 31. Stanton, P.K., Winterer, J., Bailey, C.P., Kyrozis, A., Raginov, I., Laube, G., Veh,  
578 R.W., Nguyen, C.Q. & Müller, W. Long-term depression of presynaptic release from  
579 the readily-releasable vesicle pool induced by NMDA receptor-dependent retrograde  
580 nitric oxide. *J. Neurosci.* 23, 5936-5944 (2003).
- 581 32. Clements, J.D. & Silver, R.A. Unveiling synaptic plasticity: a new graphical and  
582 analytical approach. *Trends Neurosci.* 23, 105-113 (2000).
- 583 33. Silver, R.A. Estimation of nonuniform quantal parameters with multiple-probability  
584 fluctuation analysis: theory, application and limitations. *J. Neurosci. Methods* 130,  
585 127-141 (2003).


- 586 34. Silver, R.A., Momiyama, A. & Cull-Candy, S.G. Locus of frequency-dependent  
587 depression identified with multiple-probability fluctuation analysis at rat climbing fibre-  
588 Purkinje cell synapses. *J. Physiol.* 510, 881-902 (1998).
- 589 35. Reid, C.A. & Clements, J.D. Postsynaptic expression of long-term potentiation in the  
590 rat dentate gyrus demonstrated by variance-mean analysis. *J. Physiol.* 518, 121-30  
591 (1999).
- 592 36. Oleskevich, S., Clements, J. & Walmsley, B. Release probability modulates short-  
593 term plasticity at a rat giant terminal. *J. Physiol.* 524, 513-523 (2000).
- 594 37. Foster, K.A. & Regehr, W.G. Variance-mean analysis in the presence of a rapid  
595 antagonist indicates vesicle depletion underlies depression at the climbing fiber  
596 synapse. *Neuron* 43, 119-131 (2004).
- 597 38. Peng, S., Hajela, R.K. & Atchison, W.D. Characteristics of block by  $Pb^{2+}$  of function  
598 of human neuronal L-, N-, and R-type  $Ca^{2+}$  channels transiently expressed in human  
599 embryonic kidney 293 cells. *Mol. Pharm.* 62, 1418-1430 (2002).
- 600 39. Brustein, E., Marandi, N., Kovalchuk, Y., Drapeau, P. & Konnerth, A. "In vivo"  
601 monitoring of neuronal network activity in zebrafish by two-photon  $Ca^{2+}$  imaging.  
602 *Pflugers Arch.* 446, 766-773 (2003).
- 603 40. Zhang, X.L., Upreti, C. & Stanton, P.K.  $G\beta\gamma$  and the C-terminus of SNAP-25 are  
604 necessary for long-term depression of transmitter release. *PLoS One* 6, e20500  
605 (2011).
- 606 41. Taddei, A. & Rosas-Romero, A.J. Bioactivity studies of extracts from *Tridax*  
607 *procumbens*. *Phytomedicine* 7, 235-238 (2000).
- 608 42. Bhutia, T.D. & Valant-Vetschera, K.M. Diversification of exudate flavonoid profiles in  
609 further *Primula* spp. *Nat. Prod. Commun.* 7, 587-589 (2012).

- 610 43. Jang, S.W., Liu, X., Yepes, M., Shepherd, K.R., Miller, G.W., Liu, Y., Wilson, W.D.,  
611 Xiao, G., Bianchi, B., Sun, Y.E. & Ye, K. A selective TrkB agonist with potent  
612 neurotrophic activities by 7,8-dihydroxyflavone. *Proc. Natl. Acad. Sci. USA* 107,  
613 2687-2692 (2010).
- 614 44. Zhang, Z., Liu, X., Schroeder, J.P., Chan, C.B., Song, M., Yu, S.P., Weinschenker, D.  
615 & Ye, K. 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a  
616 mouse model of Alzheimer's disease. *Neuropsychopharmacology* 39, 638-650  
617 (2014).
- 618 45. Ickes, B.R., Pham, T.M., Sanders, L.A., Albeck, D.S., Mohammed, A.H. & Granholm,  
619 A.C. Long-term environmental enrichment leads to regional increases in  
620 neurotrophin levels in rat brain. *Exp. Neurol.* 164, 45-52 (2000).
- 621 46. Rossi, C., Angelucci, A., Costantin, L., Braschi, C., Mazzantini, M., Babbini, F.,  
622 Fabbri, M.E., Tessarollo, L., Maffei, L., Berardi, N. & Caleo, M. Brain-derived  
623 neurotrophic factor (BDNF) is required for the enhancement of hippocampal  
624 neurogenesis following environmental enrichment. *Eur. J. Neurosci.* 24, 1850-1856  
625 (2006).
- 626 47. Guilarte, T.R., Toscano, C.D., McGlothan, J.L. & Weaver, S.A. Environmental  
627 enrichment reverses cognitive and molecular deficits induced by developmental lead  
628 exposure. *Ann. Neurol.* 53, 50-56 (2003).
- 629 48. Regehr, W. & Tank, D. Selective fura-2 loading of presynaptic terminals and nerve  
630 cell processes by local perfusion in mammalian brain slice. *J. Neurosci. Meth.* 37,  
631 111-119 (1991).
- 632 49. Zhang, X.L., Zhou, Z.Y., Winterer, J., Müller, W. & Stanton, P.K. NMDA-dependent,  
633 but not group I mGluR-dependent, LTD at Schaffer collateral-CA1 synapses is  
634 associated with long-term reduction of release from the rapidly recycling presynaptic  
635 vesicle pool. *J. Neurosci.* 26, 10270-10280 (2006).

636

637


638 **FIGURES**



**Figure 1:** 7,8-DHF reverses the increase in paired-pulse facilitation (PPF) produced by Pb<sup>2+</sup> exposure at Schaffer collateral-CA1 synapses in rat hippocampus. **(A)** Representative excitatory postsynaptic currents (EPSC) in field CA1 in response to Schaffer collateral paired-pulse stimuli at a 30 ms interstimulus interval (ISI) in slices from Control (CON/VEH; black trace), Pb<sup>2+</sup>-treated (Pb<sup>2+</sup>/VEH; red trace) and Pb<sup>2+</sup> + 7,8-DHF-treated rats (Pb<sup>2+</sup>/7,8-DHF; blue trace), illustrating the ability of 7,8-DHF to reverse Pb<sup>2+</sup>-induced increases in PPF. **(B)** Mean ± SEM EPSC PPF P2/P1 ratio as a function of ISI, where PPF was significantly enhanced for ISI 20-70 ms in slices from Pb<sup>2+</sup>-treated (filled red circles, N=9 slices) versus controls (open black circles, N=13 slices), and this effect was rescued by treatment of


661 Pb<sup>2+</sup> rats with 7,8-DHF (filled blue circles, N=10 slices) (p<0.05). **(C)** Mean ± SEM ratio

662 of P2/P1 (30 ms ISI) at Schaffer collateral-CA1 synapses in slices from control (open  
 663 bar), Pb<sup>2+</sup>-treated (red bar), and Pb<sup>2+</sup> plus 7,8-DHF-treated rats (blue bar), showing that  
 664 increased PPF in Pb<sup>2+</sup>-treated rats (p<0.05) was rescued by 7,8-DHF co-administration.  
 665



666  
 667 **Figure 2:** Two-photon laser scanning microscopic (TPLSM) images of FM1-43 vesicular  
 668 release from Schaffer collateral terminals in field CA1 of hippocampal slices show that  
 669 Pb<sup>2+</sup>-induced persistent reduction in release probability is rescued by 7,8-DHF. **(A)**  
 670 Representative TPLSM pseudocolor images of FM1-43 loaded presynaptic terminals in  
 671 *stratum radiatum* of field CA1 in hippocampal slices from a Pb<sup>2+</sup> rat (Pb<sup>2+</sup>/VEH), versus a

672 rat treated with  $Pb^{2+}$  plus 7,8-DHF ( $Pb^{2+}/7,8-DHF$ ), and one treated with DHF alone  
 673 (CON/7,8-DHF), or control vehicle (CON/VEH) imaged prior to (Baseline) and after 12  
 674 min 2 Hz Schaffer collateral stimulation (Calibration Bar: 5  $\mu m$ ). **(B)** Time course (Mean  
 675  $\pm$  SEM) of stimulus-evoked FM1-43 de-staining from puncta in field CA1 of hippocampal  
 676 slices in response to 2 Hz Schaffer collateral stimulation in slices from control rats (open  
 677 circles, N=8 slices, 35 puncta) versus  $Pb^{2+}$ -treated (red circles, N=6 slices, 30 puncta),  
 678 and  $Pb^{2+}$  plus 7,8-DHF-treated rats (grey diamonds, N=8 slices, 36 puncta). **(C)** Mean  $\pm$   
 679 SEM of initial fluorescence decay time constant in slices from  $Pb^{2+}$ -treated rats  
 680 ( $Pb^{2+}/VEH$ ), versus rats treated with  $Pb^{2+}$  plus 7,8-DHF ( $Pb^{2+}/7,8-DHF$ ), and control rats  
 681 treated with 7,8-DHF alone (CON/7,8-DHF) or vehicle (CON/VEH). All slices from  $Pb^{2+}$   
 682 rats showed significantly slower de-staining of Schaffer collateral terminals ( $p < 0.05$ )  
 683 compared to control slices, and this reduction was completely rescued by 7,8-DHF.




684

685


686 **Figure 3:** Chronic  $Pb^{2+}$  exposure is associated with reduced presynaptic vesicular  
 687 release probability at Schaffer collateral-CA1 terminals assessed by variance/mean  
 688 analysis. **(A)** Individual variance/mean data points, corrected to estimate  $P_r$ , at each

689  $[Ca^{2+}]_o$  for each CON/VEH/7,8-DHF (open black circles), each slice from a  $Pb^{2+}$  rat  
 690 ( $Pb^{2+}$ /VEH; open red circles), and each slice from a  $Pb^{2+}$  rat administered 7,8-DHF  
 691 ( $Pb^{2+}$ /7,8-DHF; blue circles). Data from all groups of slices were well fit by a single  
 692 parabola forced to pass through 0,0 with  $Pb^{2+}$  synapses shifted to the left, consistent  
 693 with a presynaptic reduction in  $P_r$  from chronic  $Pb^{2+}$  exposure. This shift was rescued by  
 694 7,8-DHF. **(B)** Mean  $\pm$  SEM of variance/mean points in slices from CON/VEH/7,8-DHF  
 695 (black circles; N=11),  $Pb^{2+}$ /VEH (red circles; N=8), and  $Pb^{2+}$ /7,8-DHF (blue circles; N=8),  
 696 normalized to the maximal peak amplitude recorded at 4 mM  $[Ca^{2+}]_o$ .  
 697



698  
 699 **Figure 4:** Plot of variance/mean ratio versus mean EPSC amplitude (pA) from a single  
 700 representative slice, which converts the parabolic relationship between mean and  
 701 variance to a linear one. The number of release sites (N) was derived by estimating the

702 slope of the linear fit, while the y-intercept denotes quantal size (Q) of the EPSC. The  
 703 reduction in slope indicates that chronic Pb<sup>2+</sup> exposure (Pb<sup>2+</sup>/VEH; red dotted line) was  
 704 associated with a reduction in presynaptic P<sub>r</sub>, compared to a control slice (CON/VEH;  
 705 dotted black line), that was partially reversed in a slice from a Pb<sup>2+</sup>-exposed rat  
 706 administered 7,8-DHF (Pb<sup>2+</sup>/7,8-DHF; dotted blue line).  
 707



708  
 709 **Figure 5:** 7,8-DHF rescues Pb<sup>2+</sup>-induced reductions in presynaptic Ca<sup>2+</sup> influx into  
 710 Schaffer collateral terminals. **(A)** Representative fluorescent transients evoked by  
 711 Schaffer collateral stimulation in single presynaptic terminals of a Control slice  
 712 (CON/VEH; black trace), a control slice with 7,8-DHF (CON/7,8-DHF; grey trace), a slice  
 713 from a Pb<sup>2+</sup> rat (Pb<sup>2+</sup>/VEH; red trace), and a slice from a Pb<sup>2+</sup> rat administered 7,8-DHF  
 714 (Pb<sup>2+</sup>/7,8-DHF; blue trace). **(B)** Mean ± SEM presynaptic stimulus-evoked Mg<sup>2+</sup>-Green  
 715 fluorescence increases in presynaptic terminals in response to a burst of Schaffer  
 716 collateral stimuli (4x20Hz) in slices from control (CON/VEH, N=8 slices, 16 terminals)  
 717 versus Pb<sup>2+</sup>-exposed (Pb<sup>2+</sup>/VEH, N=8 slices, 14 terminals) rats, and slices from Pb<sup>2+</sup>-  
 718 exposed rats co-administered 7,8-DHF (Pb<sup>2+</sup>/7,8-DHF, N=8 slices, 16 terminals). Ca<sup>2+</sup>



719 influx transients were significantly smaller in terminals of Pb<sup>2+</sup>-exposed rat slices  
 720 compared to either controls or 7,8-DHF rescued slices (p<0.05).

721

722

723 **Table 1:** Presynaptic release probability estimated from variance/mean analysis as a  
 724 function of ratio of [Ca<sup>2+</sup>]/[Mg<sup>2+</sup>]

Ca <sup>2+</sup> /Mg <sup>2+</sup>	CON/VEH		CON/7,8-DHF		Pb <sup>2+</sup> /VEH		Pb <sup>2+</sup> /7,8-DHF	
	Mean ± SD	N	Mean ± SD	N	Mean ± SD	N	Mean ± SD	N
1/4	0.050 ± 0.009	8	0.049 ± 0.002	3	0.037 ± 0.003 *	8	0.058 ± 0.022	8
2/1	0.451 ± 0.053	8	0.445 ± 0.052	3	0.288 ± 0.075 *	8	0.480 ± 0.058	8
4/1	0.726 ± 0.073	8	0.753 ± 0.098	3	0.603 ± 0.067 *	8	0.764 ± 0.070	8

725

726 \* = p<0.05, Student's t-test with Bonferroni correction; N= number of slices

727

728

729 **Table 2:** Numbers of release sites and quantal amplitude estimated by variance/mean  
 730 analysis at Schaffer collateral synapses in field CA1

	CON/VEH		CON/7,8-DHF		Pb <sup>2+</sup> /VEH		Pb <sup>2+</sup> /7,8-DHF	
	Mean ± SD	N	Mean ± SD	N	Mean ± SD	N	Mean ± SD	N
N. Release	144 ± 57	8	108 ± 60	8	130 ± 53	8	126 ± 58	8
Quantal Amp	2.63 ± 0.48	8	2.56 ± 0.93	8	2.53 ± 0.58	8	2.43 ± 0.79	8

731

732 N= number of slices

733